Cardiff Oncology, Inc.最新研究数据显示，将Onvansertib添加到FOLFIRI联合贝伐珠单抗（Bevacizumab）的一线标准治疗方案中，可观察到患者总体缓解率（Overall Response Rate, ORR）呈现出明显的剂量依赖性提升。这一发现进一步支持了Onvansertib在该治疗组合中的潜在价值。
Cardiff Oncology, Inc.最新研究数据显示，将Onvansertib添加到FOLFIRI联合贝伐珠单抗（Bevacizumab）的一线标准治疗方案中，可观察到患者总体缓解率（Overall Response Rate, ORR）呈现出明显的剂量依赖性提升。这一发现进一步支持了Onvansertib在该治疗组合中的潜在价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.